Second, MSLN was identified as a tumor-differentiation antigen with an overexpression discovered in multiple cancer types, such as epithelial mesothelioma, pancreatic cancer, and lung adenocarcinoma. This evidence concerns the gene MSLN and familial pancreatic carcinoma.